AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25851955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22618893 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified fruit juice (F)
Number of subjects: 123
Study 22618893 — intervention group
Group type: COMPARATOR
Intervention: Placebo fruit juice (P)
Number of subjects: 123
Study 20723994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction score for visual acuity (VA) improvement
Number of subjects: 5512
Study 20723994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction score for visual function index 14 (VF-14) improvement
Number of subjects: 5512
Study 20723994 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves
Number of subjects: 5512
Study 19246544 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal advice followed by an information sheet
Number of subjects: 700
Study 19246544 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal advice
Number of subjects: 700
Study 17089229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg before incision
Number of subjects: 60
Study 17089229 — intervention group
Group type: COMPARATOR
Intervention: Saline before incision
Number of subjects: 60
Study 17089229 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline before incision, Ketamine 0.4 mg/kg after incision
Number of subjects: 60
Study 15689053 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day
Number of subjects: 205
Study 15689053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 11508042 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training program
Number of subjects: 315
Study 11508042 — intervention group
Group type: COMPARATOR
Intervention: No social skills training
Number of subjects: 315
Study 9252161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 600 mg given orally twice daily for 36 weeks
Number of subjects: 59
Study 9252161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9252161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 59
Study 8511910 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TPN
Number of subjects: 0
Study 8511910 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TPN
Number of subjects: 0
Study 2891285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast agent (sodium meglumine diatrizoate)
Number of subjects: 34
Study 2891285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast agent (iopamidol)
Number of subjects: 34
Study 29476444 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward dose titration of pregabalin
Number of subjects: 2642
Study 29476444 — intervention group
Group type: COMPARATOR
Intervention: No upward dose titration (inadequately titrated patients)
Number of subjects: 2642
Study 29476444 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction with tolerability
Number of subjects: 2642
Study 26447636 — intervention group
Group type: COMPARATOR
Intervention: CAF+CTG (Control Group)
Number of subjects: 24
Study 26447636 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+PRF (Intervention Group)
Number of subjects: 24
Study 25371633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab followed by grid laser treatment (Group 1)
Number of subjects: 30
Study 25371633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab followed by grid laser treatment (Group 2)
Number of subjects: 30
Study 25371633 — intervention group
Group type: COMPARATOR
Intervention: Grid laser alone (Group 3)
Number of subjects: 30
Study 22228125 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebrospinal venous insufficiency (CCSVI) detection in MS patients
Number of subjects: 40
Study 22228125 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 20925997 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with clomiphene citrate (CC) and human menopausal gonadotrophin (HMG)
Number of subjects: 60
Study 20925997 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clomiphene citrate (CC) and human menopausal gonadotrophin (HMG)
Number of subjects: 60
Study 18616656 — intervention group
Group type: EXPERIMENTAL
Intervention: AST‐120
Number of subjects: 62
Study 18616656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16115974 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol‐Lipuro
Number of subjects: 60
Study 16115974 — intervention group
Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 60
Study 11954953 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (200mg, n=12)
Number of subjects: 30
Study 11954953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.2 mg/kg, n=9)
Number of subjects: 30
Study 11954953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 30
Study 9892882 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (10 mg/m2 of body surface area)
Number of subjects: 13
Study 9892882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7740291 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ASA orally daily (Group A)
Number of subjects: 27
Study 7740291 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group B)
Number of subjects: 27
Study 1338091 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy with sigmoid resection (Group I)
Number of subjects: 30
Study 1338091 — intervention group
Group type: COMPARATOR
Intervention: Polyglycolic acid mesh rectopexy without sigmoidectomy (Group II)
Number of subjects: 30
Study 1338091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 6586277 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA Regimen I (120 mg/m2/day for 5 days)
Number of subjects: 104
Study 6586277 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA Regimen II (60 mg/m2/day for 10 days)
Number of subjects: 104
Study 6586277 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA Regimen I (for ANLL)
Number of subjects: 104
Study 6586277 — intervention group
Group type: COMPARATOR
Intervention: AMSA (both regimens combined for ALL)
Number of subjects: 104
Study 6586277 — intervention group
Group type: COMPARATOR
Intervention: AMSA (for ANLL)
Number of subjects: 104
Study 6586277 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA (first course)
Number of subjects: 104
Study 6586277 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA
Number of subjects: 104
Study 30565741 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate-coated implant
Number of subjects: 16
Study 30565741 — intervention group
Group type: COMPARATOR
Intervention: Uncoated implant (Control)
Number of subjects: 16
Study 30545301 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for HCPs including General Practitioners (GP)
Number of subjects: 169
Study 30545301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 169
Study 30545301 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for HCPs
Number of subjects: 169
Study 30545301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall practices (both intervention and control)
Number of subjects: 169
Study 25086766 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 165
Study 25086766 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid Major Depressive Disorder
Number of subjects: 165
Study 25086766 — intervention group
Group type: COMPARATOR
Intervention: African Americans without PTSD
Number of subjects: 165
Study 21326328 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy (AT)
Number of subjects: 136
Study 21326328 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 136
Study 19559792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4mg once a day for a maximum of 6 weeks
Number of subjects: 21
Study 19559792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 17446823 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1089
Study 17446823 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (Control)
Number of subjects: 1089
Study 17446823 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 1089
Study 15306666 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life support (ALS)
Number of subjects: 5638
Study 15306666 — intervention group
Group type: COMPARATOR
Intervention: Rapid defibrillation (control)
Number of subjects: 5638
Study 15306666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander witnessed arrest
Number of subjects: 5638
Study 15306666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander CPR
Number of subjects: 5638
Study 15306666 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid defibrillation
Number of subjects: 5638
Study 11898372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal modulated currents (SMC) on the heart area
Number of subjects: 137
Study 11898372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal modulated currents (SMC) on the sinocarotid zones
Number of subjects: 137
Study 11898372 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedures
Number of subjects: 137
Study 9516597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense paclitaxel-containing therapy (A->T->C regimen)
Number of subjects: 0
Study 9516597 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimens
Number of subjects: 0
Study 7827298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (300 mg zinc aspartate, equal to 60 mg elemental zinc per day) for 4 weeks
Number of subjects: 14
Study 7827298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation
Number of subjects: 14
Study 3045025 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest sodium (100 mmol/day)/high potassium (130 mmol/day) diet
Number of subjects: 0
Study 3045025 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (160 mmol Na/day and 80 mmol K/day)
Number of subjects: 0
Study 30547745 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to personally-relevant music for 20 minutes every other day for six weeks
Number of subjects: 0
Study 30547745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25834076 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group 1)
Number of subjects: 39
Study 25834076 — intervention group
Group type: COMPARATOR
Intervention: Regular, ongoing therapy (Group 3)
Number of subjects: 39
Study 25834076 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injections (Group 2)
Number of subjects: 39
Study 23833857 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LVHC: 0.5 ml/kg bupivacaine 0.375% (1.875 mg/kg)
Number of subjects: 50
Study 23833857 — intervention group
Group type: COMPARATOR
Intervention: Group C: 1 ml/kg bupivacaine 0.25% (2.5 mg/kg)
Number of subjects: 50
Study 21079463 — intervention group
Group type: EXPERIMENTAL
Intervention: anesthetic spray
Number of subjects: 84
Study 21079463 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo spray
Number of subjects: 84
Study 21079463 — intervention group
Group type: EXPERIMENTAL
Intervention: anesthetic intradermal injection
Number of subjects: 84
Study 21079463 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo intradermal injection
Number of subjects: 84
Study 21079463 — intervention group
Group type: COMPARATOR
Intervention: control group with no local anesthetic agent
Number of subjects: 84
Study 18398105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE)
Number of subjects: 10739
Study 18398105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 16632763 — intervention group
Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 6, 12, and 18 months
Number of subjects: 461
Study 16632763 — intervention group
Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 3, 12, and 15 months
Number of subjects: 461
Study 16632763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EC40 varnish)
Number of subjects: 461
Study 14638334 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin
Number of subjects: 0
Study 14638334 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b plus ribavirin
Number of subjects: 0
Study 8843494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (6 gm daily)
Number of subjects: 11
Study 8843494 — intervention group
Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 11
Study 1423178 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 103
Study 1423178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and methotrexate (CAM)
Number of subjects: 103
Study 3865493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 20 mg/kg body weight b.i.d. for 10 days
Number of subjects: 91
Study 3865493 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 91
Study 3865493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor treatment
Number of subjects: 91
Study 30930801 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy (n = 71)
Number of subjects: 142
Study 30930801 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 71)
Number of subjects: 142
Study 28281353 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out arm (received a letter stating they were enrolled with the option to opt out)
Number of subjects: 569
Study 28281353 — intervention group
Group type: COMPARATOR
Intervention: Opt-in arm (received a standard recruitment letter)
Number of subjects: 569
Study 27659878 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic TYRX absorbable envelope
Number of subjects: 7764
Study 27659878 — intervention group
Group type: COMPARATOR
Intervention: No Medtronic TYRX absorbable envelope (Control)
Number of subjects: 7764
Study 24518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin drug use
Number of subjects: 9457
Study 24518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of statin use
Number of subjects: 9457
Study 22388296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1309
Study 20698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous AA subjects
Number of subjects: 36
Study 20698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous AG subjects
Number of subjects: 36
Study 20698837 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intoxication
Number of subjects: 36
Study 16953394 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride at a daily dose of 1,500 mg for 12 weeks along with conventional medication
Number of subjects: 51
Study 16953394 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks along with conventional medication
Number of subjects: 51
Study 16953394 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 51
Study 16953394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16193895 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 396
Study 16193895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 12398260 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 50 mg x 24 h(‐1)
Number of subjects: 6
Study 12398260 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation (SD)
Number of subjects: 6
Study 12398260 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period after SD
Number of subjects: 6
Study 12398260 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 150 mg x 24 h(‐1)
Number of subjects: 6
Study 12398260 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg x 24 h(‐1)
Number of subjects: 6
Study 9915885 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-FOS 10 g/d
Number of subjects: 40
Study 9915885 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-FOS 20 g/d
Number of subjects: 40
Study 9915885 — intervention group
Group type: COMPARATOR
Intervention: SC-FOS 0 g/d (Control)
Number of subjects: 40
Study 9915885 — intervention group
Group type: COMPARATOR
Intervention: SC-FOS 2.5 g/d (Control)
Number of subjects: 40
Study 9915885 — intervention group
Group type: COMPARATOR
Intervention: SC-FOS 5 g/d (Control)
Number of subjects: 40
Study 7766747 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl (10 mg)
Number of subjects: 30
Study 7766747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (30 g)
Number of subjects: 30
Study 7766747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (45 g)
Number of subjects: 30
Study 7766747 — intervention group
Group type: COMPARATOR
Intervention: Control (standard conditions)
Number of subjects: 30
Study 2271369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 10
Study 2271369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 10
Study 2271369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 38177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (high-dose suppressive therapy)
Number of subjects: 0
Study 38177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (prophylactic dose)
Number of subjects: 0
Study 38177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (high dose)
Number of subjects: 0
Study 38177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (low dose)
Number of subjects: 0
Study 38177 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight)
Number of subjects: 0
Study 38177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38177 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (general)
Number of subjects: 0
Study 30626147 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort meal ingestion in women
Number of subjects: 20
Study 30626147 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort meal ingestion in men
Number of subjects: 20
Study 30626147 — intervention group
Group type: COMPARATOR
Intervention: Comparison of meal experience between genders
Number of subjects: 20
Study 24954156 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatments
Number of subjects: 2280
Study 24954156 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitted patients
Number of subjects: 2280
Study 24954156 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month follow-up
Number of subjects: 2280
Study 24156138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% arginine/Dical/1450 ppm fluoride
Number of subjects: 0
Study 24156138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% arginine/calcium carbonate/1450 ppm fluoride
Number of subjects: 0
Study 24156138 — intervention group
Group type: COMPARATOR
Intervention: Positive control (Dical and 1450 ppm fluoride)
Number of subjects: 0
Study 24156138 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Dical and 250 ppm fluoride)
Number of subjects: 0
Study 24156138 — intervention group
Group type: COMPARATOR
Intervention: Positive control (1450 ppm fluoride)
Number of subjects: 0
Study 24156138 — intervention group
Group type: COMPARATOR
Intervention: Negative control (250 ppm fluoride)
Number of subjects: 0
Study 24156138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% arginine/calcium carbonate/1000 ppm fluoride
Number of subjects: 0
Study 24156138 — intervention group
Group type: COMPARATOR
Intervention: Positive control (1000 ppm fluoride)
Number of subjects: 0
Study 24156138 — intervention group
Group type: COMPARATOR
Intervention: Negative control (0 ppm fluoride)
Number of subjects: 0
Study 21122849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electrical stimulation (AES) at true acupoints
Number of subjects: 90
Study 21122849 — intervention group
Group type: COMPARATOR
Intervention: Acupoint electrical stimulation (AES) at sham acupoints
Number of subjects: 90
Study 21122849 — intervention group
Group type: COMPARATOR
Intervention: No intervention with AES (control group)
Number of subjects: 90
Study 18810547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 140
Study 18810547 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (14 mmHg)
Number of subjects: 140
Study 16637835 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin
Number of subjects: 14
Study 16637835 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% lomefloxacin
Number of subjects: 14
Study 16637835 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin
Number of subjects: 14
Study 15327586 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin-free epoetin alfa (6000 IU per subject)
Number of subjects: 60
Study 15327586 — intervention group
Group type: COMPARATOR
Intervention: Gelatin-containing epoetin alfa (6000 IU per subject)
Number of subjects: 60
Study 15327586 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin-free epoetin alfa (750 IU per subject)
Number of subjects: 60
Study 11759309 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 34
Study 9249269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline‐induced sputum
Number of subjects: 18
Study 8392345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 12
Study 8392345 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 12
Study 8392345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH) and Unfractionated heparin (UFH)
Number of subjects: 12
Study 3440388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering blood cholesterol through various recruitment methods (not specified in detail)
Number of subjects: 0
Study 30871639 — intervention group
Group type: EXPERIMENTAL
Intervention: lambda‐cyhalothrin with pheromone + residual insecticide spray (PI)
Number of subjects: 788